|
Robert W. Pollock, R.Ph., M.S. is Senior Vice President of Lachman Consultant Services, Inc. Formerly, Mr. Pollock was the Acting Deputy Director of the Office of Generic Drugs (OGD), Center for Drug Evaluation and Research, Food and Drug Administration. He was in the Generic Drugs Program shortly after the passage of the Drug Price Competition and Patent Term Restoration Act (Waxman-Hatch Act). Prior to transferring to the FDA in 1985, he held various field and headquarters assignments with the Health Resources and Services Administration of the Public Health Service. He retired from the PHS in January 1995 with over 20 years of service at the rank of Captain. Mr. Pollock received his B.S. degree in Pharmacy and his M.S. degree in Pharmacy Administration at the University of Rhode Island where he studied as a Fellow of the American Foundation for Pharmaceutical Education. Mr. Pollock has numerous publications and has presented extensively on the drug approval process as well as issues regarding strategic alliances. | 